Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: Patient considerations

Drug, Healthcare and Patient Safety

Volumn 2, Issue 1, 2010, Pages 101-119

  Horton, Sarah ^a   Buch, Maya H ^b   Emery, Paul ^b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Abatacept; Biologic therapy; Rheumatoid arthritis; Rituximab; Safety; Tocilizumab; Tumor necrosis factor

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PLACEBO; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ANAPHYLAXIS; ASPERGILLOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; BACKACHE; BIOLOGICAL THERAPY; BONE EROSION; CANCER RISK; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEMYELINATING DISEASE; DISEASE ACTIVITY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA NODOSUM; HEART FAILURE; HEMATOLOGIC DISEASE; HEPATITIS B; HEPATITIS C; HISTOPLASMOSIS; HUMAN; HYPERTENSION; IMMUNOGENICITY; INFECTION; INJECTION SITE REACTION; JOINT RADIOGRAPHY; LUNG CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NEUTROPENIA; NONHODGKIN LYMPHOMA; PANCYTOPENIA; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; QUALITY OF LIFE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SJOEGREN SYNDROME; SKIN CANCER; SOLID TUMOR; SPONTANEOUS ABORTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VASCULITIS; VIRUS REACTIVATION;

EID: 77957153556     PISSN: None     EISSN: 11791365     Source Type: Journal    
DOI: 10.2147/DHPS.S6317     Document Type: Review

References (93)

1. Helmick CG, Felson DT, Lawrence RC, et al; National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Arthritis Rheum. 2008;58: 15-25.
2. Södergren A, Stegmayr B, Lundberg V, Öhman ML, Wållberg-Jonsson S. Increased incidence of and impaired prognosis after acute myocardial infarction among patients with seropositive rheumatoid arthritis. Ann Rheum Dis. 2007;66: 263-266.
3. Yelin E, Henke C, Epstein W. The work dynamics of the person with rheumatoid arthritis. Arthritis Rheum. 1987;30: 507-512.
4. Machold KP, Stamm TA, Enbrel GJM, et al. Very recent onset arthritis - clinical, laboratory, and radiological findings during the first year of disease. J Rheumatol. 2002;29: 2278-2287.
5. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364: 263-269.
6. Verstappen SMM, Jacobs JWG, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis. 2007;66: 1443-1449.
7. Choy EHS, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344: 909-916.
8. Felson DT, Anderson JJ, Boers M, et al. ACR preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38: 727-735.
9. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE. Determining minimally important changes in generic and disease-specific healthrelated quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum. 2000;43: 1478-1487.
10. Genant HK, Peterfy CG, Westhovens R, et al. Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the longterm extension of the AIM trial. Ann Rheum Dis. 2008;67: 1084-1089.
11. Maini R, St Clair EW, Breedveld F, et al; the ATTRACT Study Group. Infliximab (chimeric anti-tumour necrosis factor monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet. 1999;354: 1932-1939.
12. Lipsky PE, van der Heijde DMFM, St Clair EW, et al; the ATTRACT Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;30: 1594-1602.
13. St Clair EW, van der Heijde DMFM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis. A randomized, controlled trial. Arthritis Rheum. 2004;50: 3432-3443.
14. Goerkoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis. A randomised trial. Ann Intern Med. 2007;146: 406-415.
15. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. The ARMADA trial. Arthritis Rheum. 2003;48: 35-45.
16. van der Putte LBA, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004;63: 508-516.
17. Breedveld FC, Weisman MH, Kavanaugh AF, et al; the PREMIER Investigators. The PREMIER study. A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54: 26-37.
18. Bejarano V, Quinn M, Conaghan PG, et al; Yorkshire Early Arthritis Register Consortium. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum. 2008;59: 1467-1474.
19. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumour necrosis factor receptor: Fc fusion protein in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340: 253-259.
20. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomised, controlled trial. Ann Intern Med. 1999;130: 478-486.
21. Klareskog L, van der Heidje D, de Jager JP, et al; for the TEMPO investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004; 363: 675-681.
22. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372: 375-382.
23. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. New Engl J Med. 2000;343: 1586-1593.
24. Keystone E, van der Heijde D, Mason D Jr, et al. Certolizumab pegol plus methotrexate is significantly more effective in active rheumatoid arthritis: findings of a fifty-two-week, phase III multicenter, randomised, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 2009;58: 3319-3329. Epub 2008 Oct 30.
25. Smolen JS, Landewé RBM, Mease PJ, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. Ann Rheum Dis. 2009 Jun;68: 797-804. Epub 2008 Nov 17.
26. Fleischmann R, Vencovsky J, van Vollenhoven, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis. 2009 Jun;68: 805-811. Epub 2008 Nov 17.
27. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to TNFα given by subcutaneous injections, active rheumatoid arthritis despite methotrexate: the GO-FORWARD study. Ann Rheum Dis. 2009;68: 789-796.
28. Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a new human anti-TNFα monoclonal antibody, administered subcutaneously every 4 weeks in methotrexate-naive patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, GO-BEFORE study. Ann Rheum Dis. 2008; 67 Suppl 2: S179.
29. Smolen JS, Kay J, Doyle MK, et al; the GO-AFTER study investigators. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009;374: 210-221.
30. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41: 1552-1563.
31. Maini RN, Breedveld FC, Kalden JR, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. 2004;50: 1051-1065.
32. Breedveld FC, Emery P, Keystone E, et al. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis. 2004;63: 149-155.
33. Quinn MA, Conaghan PG, O'Connor PJ, et al. Very early treatment with inflximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imagng evidenc of synovitis and damage with sustained benefit after infliximab withdrawal. Arthritis Rheum. 2005;52: 27-35.
34. Bejerano V, Conaghan P, Quinn M, Saleem B, Emery P. Benefits eight years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis. Rheumatology. Submitted 2010.
35. Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis. 2006;65: 753-759.
36. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti - tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. A randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004; 50: 1400-1411.
37. Emery P, Genovese MC, van Vollenhoven R, Sharp JT, Patra K, Sasso EH. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. J Rheumatol. 2009; 36: 1429-1441.
38. Kimel M, Cifaldi M, Chen N, Revicki D. Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA. J Rheumatol. 2008;35: 206-215.
39. Van der Heijde D, Klareskog L, Singh A, et al. Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial. Ann Rheum Dis. 2005;65: 328-334.
40. Emery P, Breedveld F, van der Heijde D, et al; Combination of Methotrexate and Etanercept in Early Rheumatoid Arthritis Trial Group. Two-year clinical and radiographic results with combination etanerceptmethotrexate therapy versus monotherapy in early rheumatoid arthritis. Arthritis Rheum. 2010;62: 674-682.
41. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis. Two-year radiographic and clinical outcomes. Arthritis Rheum. 2002;46: 1443-1450.
42. Genovese MC, Bathon JM, Fleischmann RM, et al. Long-term safety, efficacy and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol. 2005;32: 1232-1242.
43. Genant HK, Peterfy CG, Westhovens R, et al. Abatacept inhibits progression of structural damage in rhuematoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis. 2008;67: 1084-1089. Epub 2007 Dec 17.
44. Kremer JM, Geneant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomised trial. Ann Intern Med. 2006;144: 866-876.
45. Kremer JM, Dougados M, Emery P, et al. Treatement of rheumatoid arthritis with selective costimulation modulator abatacept. Arthritis Rheum. 2005;52: 2263-2271.
46. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumour necrosis factor alpha inhibition. N Engl J Med. 2005;353: 1114-1123.
47. Kremer JM, Geneant HK, Moreland LW, et al. Results of a two-year follow up study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum. 2008;58: 953-963.
48. Westhovens R, Kremer JM, Moreland LW, et al. Safetey and efficacy of the selective costimulation modulator abatacept in pateints with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. J Rheumatol. 2009;36: 736-742.
49. Genovese MC, Schiff M, Luggen M, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis. 2008;67: 547-554.
50. Westhovens R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naïve patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis. Epub 2009 Jan 5.
51. Emery P, Durez P, Dougados M, et al. The impact of T-cell co- stimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept. Ann Rheum Dis. Epub 2009 Nov 23.
52. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31: 315-324.
53. Emery P, Fleischmann R, Filipowicz-Ssnowska A, et al; the DANCER study group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Arthritis Rheum. 2006;54: 1390-1400.
54. Furst DE, Breedvald FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis. 2007;66 Suppl 3: S2-S22.
55. Smolen JS, Keystone EC, Emery P, et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66: 143-150.
56. Dass S, Rawstron AC, Vital EM, Henshaw K, McGonagle D, Emery P. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum. 2008;58: 2993-2999.
57. Vital EM, Dass S, Rawstron AC, et al. Management of non-response to rituximab in rheumatoid arthritis: predictors and outcome of retreatment. Arthritis Rheum. In press 2010.
58. Edwards JCW, Szczepański L, Szechiński J, et al. Efficacy of B-cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350: 2572-2581.
59. Mease PJ, Revick DA, Szechinski J, et al. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab - results of the dose-ranging assessment: international clinical evaluation of rituximab in rheumatoid arthritis (DANCER) trial. J Rheumatol. 2008;35: 20-30.
60. Cohen SB, Emery P, Greenwald MW, et al; the REFLEX trial group. Rituximab for rheumatoid arthritis refractory to anti-tumour necrosis factor therapy. Arthritis Rheum. 2006;54: 2793-2806.
61. Muraguchi A, Hirano T, Tang B, et al. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med. 1988;167: 332-344.
62. Lotz M, Jirik F, Kabouridis P, et al. B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes. J Exp Med. 1989;557: 417-435.
63. Maini RN, Taylor PC, Szechinski J, et al; for the CHARISMA study group. Double-blind randomised controlled clinical trial of the interleukin- 6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54: 2817-2829.
64. Smolen JS, Bealieu A, Rubbert-Roth A, et al; for the OPTION investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371: 987-997.
65. Genovese MC, McKay JD, Nasonev EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 2008;58: 2968-2980.
66. Emery P, Keystone E, Tony HP, et al. Il-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67: 1516-1523. Epub 2008 Jul 14.
67. Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66: 1162-1167. Epub 2007 May 7.
68. Kremer J, Fleischmann RM, Saurigny D, Alecock E, Blanco R. Safety and tolerability of tocilizumab in combination with methotrexate (MTX) in patients with rheumatoid arthritis and inadequate response to MTX: 1-year results of the LITHE study. Ann Rheum Dis. 2009;68 Suppl 3: 444.
69. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. Epub 2009 March 17.
70. Smolen JS, Alten RHE, Gomez-Reino J, et al. Efficacy of tocilizumab in rheumatoid arthritis: interim analysis of long-term extension trials of up to 2.5 years. Ann Rheum Dis. 2009;68 Suppl 3: 401.
71. Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti-tumour necrosis factor-α monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (safety trial of adalimumab in rheumatoid arthritis). J Rheumatol. 2003;30: 12.
72. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. JAMA. 2006;295: 2275-2285.
73. Salliot C, Gossec L, Ruyssen-Witrand A, et al. Infections during tumour necrosis factor-α blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology. 2007;46: 327-334.
74. Dixon WG, Symmons DPM, Lunt M, Watson KD, Hyrich KL, Silman AJ. British Society for Rheumatology Biologics Register Control Centre Consortium. Serious infection following anti-tumor necrosis factor-α therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies. Arthritis Rheum. 2007;56: 2896-2904.
75. Van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of rituximab: follow-up of the RA clinical trials and the re-treatment population. Ann Rheum Dis. 2009;68 Suppl 3: 76.
76. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. Epub 2009 Oct 22.
77. Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Sem Arth Rheum. 2006;36: 159-167.
78. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, et al; BIOBADASER Group. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 2005;52: 1766-1772.
79. Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Bes Pract Res Clin Rheum. 2006;20: 757-790.
80. Peterson JR, Hsu FC, Simkin PA, Wener MH. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viremia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis. 2003;62: 1078-1082.
81. Zein NN; Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naïve patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebocontrolled study. J Hepatol. 2005;42: 315-322.
82. Amari W, Zeringue AL, McDonald JR, et al. Non-melanoma and melanoma skin cancer risk in a national cohort of veterans with rheumatoid arthritis. ACR 2008, Abstract 1379. Available from: http://acr.confex.com/acr/2009/webprogram/Paper11467.html
83. Askling J, Fored CM, Brandt L, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis. 2005;64: 1421-1426.
84. Dixon W, Watson KD, Lunt M, et al. The influence of anti-TNF therapy upon cancer incidence in patients with rheumatoid arthritis (RA) who have had prior malignancy: results from the BSRBR. Arthritis Rheum. 2008;58 Suppl: S638-S639.
85. Mariette X, Tubach F, Ravaud P, et al. Patients on anti-TNF have an increased risk of lymphoma compared with the general population: results of the French RATIO observatory. Ann Rheum Dis. 2008;67 Suppl 2: 323.
86. Askling J, Fored CM, Baecklund E, et al. Hematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis. 2005;64: 1414-1420.
87. Westhovens R, Yocum D, Han J, et al; START Study Group. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum. 2006;54: 1075-1086.
88. Harrison MJ, Dixon WG, Watson KD, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-TNFα therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2009;68: 209-215.
89. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113: 4834-4840. Epub 2009 March 5.
90. Mann D, McMurray J, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failue: results of the randomised etanercept worldwide evaluation (RENEWAL). Circulation. 2004;109: 1594-1602.
91. Hyrich KL, Symmons DPM, Watson KD, Silman AJ. Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register. Arthritis Rheum. 2006;54: 2701-2702.
92. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ. Outcomes after switching from one anti-tumour ncrosis factor alpha agent to a second anti-tumour necrosis factor agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum. 2007;66: 893-899.
93. Ikeda K, Cox S, Emery P. Biological therapy in early arthritis - overtreatment or the way to go? Arthritis Res Ther. 2007;9: 211-217.